6/23/2026

Activated Charcoal Oral Suspension

Products Affected - Description

- Actidose Aqua oral suspension, Padagis, 15 gram/72 mL, tube, NDC 00574-0521-25
- Actidose Aqua oral suspension, Padagis, 25 gram/120 mL, tube, NDC 00574-0521-74
- Actidose Aqua oral suspension, Padagis, 50 gram/240 mL, tube, NDC 00574-0521-76
- Actidose with Sorbitol oral suspension, Padagis, 25 gram/120 mL, tube, NDC 00574-0520-74
- Actidose with Sorbitol oral suspension, Padagis, 50 gram/240 mL, tube, NDC 00574-0520-76
- Insta-Char oral suspension, Vista Pharma, 25 gram/240 mL, unflavored, bottle, NDC 66689-0113-08
- Insta-Char in Sorbitol oral suspension, Vista Pharma, 25 gram/240 mL, cherry flavor, bottle, NDC 66689-0115-08

Reason for the Shortage

- Padagis has temporarily discontinued Actidose Aqua and Actidose with Sorbitol. The company is working with FDA to reformulate to a 25 gram /240 mL product for both the Actidose Aqua and Actidose with Sorbitol products.
- PAI (VistaPharm) did not provide a reason for the shortage.

Available Products

- Insta-Char oral suspension, Vista Pharma, 25 gram/240 mL, cherry flavor, bottle, NDC 66689-0114-08

Estimated Resupply Dates

- Padagis has temporarily discontinued Actidose Aqua and Actidose with Sorbitol and the company cannot estimate when product will return to market.
- PAI (VistaPharm) has Insta-Char 25 gram/240 mL bottles (unflavored) available with short expiration dating (March 2027). Insta-Char in Sorbitol 25 gram/240 mL bottles (cherry flavor) are also available with short expiration dating (September 2026).

Updated

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.